Yayın:
Varicella vaccine

dc.contributor.buuauthorÇelebi, Solmaz
dc.contributor.buuauthorÇELEBİ, SOLMAZ
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentÇocuk Sağlığı ve Hastalıkları Ana Bilim Dalı
dc.date.accessioned2024-10-01T10:13:22Z
dc.date.available2024-10-01T10:13:22Z
dc.date.issued2009-05-01
dc.description.abstractVaricella-zoster virus (VZV) infection causes two clinically distinct forms of disease: varicella and herpes zoster. Primary VZV infection results in the diffuse vesicular rash of varicella, or chickenpox. Whereas chickenpox is a mild disease in otherwise healthy children, varicella virus in an immunodeficient individual may lead to a more serious form. The epidemiology of varicella has changed dramatically since the introduction of the varicella vaccine in 1995. Two live, attenuated varicella zoster virus-vaccines are licensed in the United States for the prevention of chickenpox. Varicella vaccine is licensed for use in healthy children at 12 months of age.
dc.identifier.endpage11
dc.identifier.issn1307-1068
dc.identifier.issueSupplement1
dc.identifier.startpage8
dc.identifier.urihttps://hdl.handle.net/11452/45589
dc.identifier.volume3
dc.identifier.wos000422185600003
dc.indexed.wosWOS.ESCI
dc.language.isoen
dc.publisherAves Yayincilik, Ibrahim Kara
dc.relation.journalJournal Of Pediatric Infection
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.subjectVaricella
dc.subjectHerpes zoster
dc.subjectImmunization
dc.subjectScience & technology
dc.subjectLife sciences & biomedicine
dc.subjectPediatrics
dc.titleVaricella vaccine
dc.typeArticle
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/Çocuk Sağlığı ve Hastalıkları Ana Bilim Dalı
local.indexed.atWOS
relation.isAuthorOfPublication28076e30-7802-4de2-ae05-028643d56968
relation.isAuthorOfPublication.latestForDiscovery28076e30-7802-4de2-ae05-028643d56968

Dosyalar